GW pharma sees price action as Sativex approval finally looms

GW pharma (GWP) moved up around 10% early this afternoon but fell back to close up 5% at 128p. Although volumes were not dramatic on the buy side, this move is presumably linked to imminent Sativex approval in the U.K. and/or market makers adjusting bid/offer levels on a shortage of stock for a larger buyer waiting in the wings i.e. encouraging profit taking by smaller shareholders as their positions increased in value.